HighVista Strategies LLC Invests $1.39 Million in ADMA Biologics Inc $ADMA

HighVista Strategies LLC purchased a new stake in ADMA Biologics Inc (NASDAQ:ADMA) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 95,112 shares of the biotechnology company’s stock, valued at approximately $1,394,000.

A number of other hedge funds have also modified their holdings of ADMA. American Century Companies Inc. boosted its position in ADMA Biologics by 8.4% during the 2nd quarter. American Century Companies Inc. now owns 4,610,989 shares of the biotechnology company’s stock worth $83,966,000 after acquiring an additional 358,627 shares during the last quarter. Thrivent Financial for Lutherans raised its holdings in shares of ADMA Biologics by 24.9% in the third quarter. Thrivent Financial for Lutherans now owns 4,141,840 shares of the biotechnology company’s stock valued at $60,719,000 after purchasing an additional 826,415 shares during the last quarter. Ranger Investment Management L.P. lifted its position in shares of ADMA Biologics by 49.1% in the second quarter. Ranger Investment Management L.P. now owns 2,390,375 shares of the biotechnology company’s stock worth $43,529,000 after purchasing an additional 786,865 shares in the last quarter. WINTON GROUP Ltd lifted its position in shares of ADMA Biologics by 302.8% in the second quarter. WINTON GROUP Ltd now owns 272,817 shares of the biotechnology company’s stock worth $4,968,000 after purchasing an additional 205,094 shares in the last quarter. Finally, Harbor Capital Advisors Inc. acquired a new position in ADMA Biologics during the third quarter worth $877,000. 75.68% of the stock is currently owned by institutional investors.

Insider Buying and Selling at ADMA Biologics

In other news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $15.63, for a total value of $157,800.48. Following the transaction, the chief operating officer directly owned 466,600 shares of the company’s stock, valued at $7,292,958. This represents a 2.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Steve Elms bought 7,000 shares of the business’s stock in a transaction dated Thursday, March 5th. The shares were bought at an average price of $15.67 per share, with a total value of $109,690.00. Following the purchase, the director owned 2,038,730 shares in the company, valued at $31,946,899.10. The trade was a 0.34% increase in their position. The SEC filing for this purchase provides additional information. 3.70% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

ADMA has been the topic of several recent research reports. Weiss Ratings reiterated a “hold (c)” rating on shares of ADMA Biologics in a research note on Tuesday, December 23rd. Wall Street Zen upgraded ADMA Biologics from a “hold” rating to a “buy” rating in a report on Saturday, February 28th. Finally, Zacks Research raised ADMA Biologics from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 2nd. Two analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $32.00.

ADMA Biologics Stock Up 1.1%

ADMA Biologics stock opened at $15.15 on Monday. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.71 and a quick ratio of 3.74. The company’s 50-day moving average is $16.63 and its 200-day moving average is $16.70. The firm has a market capitalization of $3.61 billion, a PE ratio of 25.25 and a beta of 0.51. ADMA Biologics Inc has a fifty-two week low of $13.76 and a fifty-two week high of $25.67.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.20. ADMA Biologics had a net margin of 28.80% and a return on equity of 37.52%. The business had revenue of $139.16 million during the quarter, compared to the consensus estimate of $139.80 million. During the same period last year, the business posted $0.46 EPS. ADMA Biologics’s revenue was up 18.4% on a year-over-year basis. Sell-side analysts anticipate that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.